Evidence map›Paper›PMID 37668586›Full record

ArticleEuropean journal of haematology2023

Association of iron therapy with incidence of chronic kidney disease.

Prabin Shrestha, Shejuti Paul, Keiichi Sumida, Fridtjof Thomas, Satya Surbhi, Abu Mohd Naser, Elani Streja, Connie M Rhee, Kamyar Kalantar-Zadeh, Csaba P Kovesdy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of haematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Prabin ShresthaDivision of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Shejuti PaulDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Keiichi SumidaDivision of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Fridtjof ThomasDepartment of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Satya SurbhiDepartment of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Abu Mohd NaserDivision of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee, USA.
Elani StrejaDivision of Nephrology and Hypertension, University of California-Irvine, Orange, California, USA.
Connie M RheeDivision of Nephrology and Hypertension, University of California-Irvine, Orange, California, USA.
Kamyar Kalantar-ZadehLong Beach VA Medical Center, Long Beach, California, USA.
Csaba P KovesdyDivision of Nephrology, University of Tennessee Health Science Center, Memphis, Tennessee, USA.ORCID https://orcid.org/0000-0002-8204-911X
University of Tennessee Health Science Center · USUniversity of California, Irvine · USUCLA Medical Center · USUniversity of Memphis · US

Funding

Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource CenterHSRD VA I01 HX002680Memphis and Long Beach VA Medical CentersUS Department of Veterans Affairs Health Services Research and Development Service (HSR&D) I01HX002680
6 · The paper itself

Abstract

objectiveWe investigated the association of oral iron replacement with the incidence of chronic kidney disease (CKD) in a population with normal kidney function to study the effects of iron replacement on the development of new onset CKD.

methodsIn a national cohort of US Veterans with no pre-existing CKD, we identified 33 894 incident new users of oral iron replacement and a comparable group of 112 780 patients who did not receive any iron replacement during 2004-2018. We examined the association of oral iron replacement versus no iron replacement with the incidence of eGFR <60 mL/min/1.73 m

resultsIn the cohort of 146 674 patients, a total of 18 547 (13%) patients experienced incident eGFR <60 mL/min/1.73 m

conclusionOral iron replacement is associated with higher risk of new onset CKD. The long-term kidney safety of oral iron replacement should be tested in clinical trials.

Indexed as

Renal Insufficiency, ChronicCreatinineGlomerular Filtration RateHumansIncidenceIronKidneyCreatinineIronalbuminuriachronic kidney diseaseeGFRiron replacement

Identifiers

PMID37668586
PMCPMC13032773
OpenAlexW4386439150

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.